Welcome to our dedicated page for 89Bio news (Ticker: ETNB), a resource for investors and traders seeking the latest updates and insights on 89Bio stock.
89Bio, Inc. (NASDAQ: ETNB) is a clinical-stage biopharmaceutical company pioneering therapies for liver and cardiometabolic diseases, with its lead candidate pegozafermin advancing through Phase 3 trials. This page serves as the authoritative source for all official company updates, including clinical developments, regulatory milestones, and strategic partnerships.
Investors and researchers will find timely updates on-therapeutic progress for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The curated news collection provides essential context on trial designs, scientific publications, and market developments relevant to 89Bio's glycoPEGylated FGF21 analog platform.
All content is rigorously verified to ensure compliance with financial disclosure regulations. Bookmark this page for structured access to 89Bio's progress in addressing critical unmet medical needs through innovative biopharmaceutical research.
89bio, Inc. (Nasdaq: ETNB) has announced the pricing of its public offering of 16,923,077 shares of common stock at $16.25 per share, which will raise approximately $275 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 2,538,461 shares. The offering is expected to close around March 28, 2023, subject to customary conditions. BofA Securities, SVB Securities, and Evercore ISI are acting as lead book-running managers. 89bio focuses on innovative therapies for liver and cardio-metabolic diseases, with its lead candidate targeting non-alcoholic steatohepatitis (NASH).
89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), announced a public offering of $200 million in common stock or pre-funded warrants. The offering includes a 30-day option for underwriters to purchase an additional $30 million. Proceeds will support clinical activities for pegozafermin, focusing on liver and cardio-metabolic diseases. The offering is subject to market conditions. BofA Securities, SVB Securities, and Evercore ISI are the book-running managers. The company emphasizes that this press release is not an offer to sell securities, as per SEC regulations.
FAQ
What is the current stock price of 89Bio (ETNB)?
What is the market cap of 89Bio (ETNB)?
